2019 Parkinson Study Group Symposium and Training

摘要 拟议的三年会议项目，以年度临床研究研讨会为中心， 帕金森研究小组（PSG）和相关的年会活动，将促进教育和 培训早期研究人员，以确保最高质量的转化和临床研究 继续致力于改善帕金森氏症和相关神经系统疾病的治疗。 该项目的目标将通过两个具体目标（SA）实现。在SA #1中，PSG将展示其 “第32届帕金森病病因、发病机制和治疗年度研讨会， 其他运动障碍”与亨廷顿研究小组（HSG）合作，肌张力障碍研究 组（DSG）、抽动秽语综合征研究组（TSSG）、合作性共济失调组（CAG）和震颤 研究小组（TRG）于2019年4月6日星期六在亚利桑那州凤凰城举行，第33和第34次研讨会 此后每年。同行评审的计划包括平台和海报演示在一个现场 有观众参与的形式。专题讨论会的主题将讨论主要挑战 和机会，以寻求改善治疗帕金森氏症和其他 神经退行性疾病，主题演讲传达互补的神经生物学，临床 发展和病人的观点。2019年研讨会将涵盖PD的革命性影响 遗传学，特别是GBA和LRRK2突变，对PD疗法的发展。#2是 旨在为运动障碍的早期临床研究者提供多方面的培训， 注重PD临床研究的实用性。被选中的初级调查员将参加几个 新颖的和互动的，教育研究活动，除了专题讨论会，包括a）直接 与帕金森基金会的PAIR（帕金森氏症）经验丰富的患者倡导者交流 研究倡导者）计划，以了解患者的意见如何使其研究受益，以及B）PSG 指导委员会的初级研究者技能研讨会，每年轮换主题，涵盖临床 研究项目开发，赠款提案写作，和新兴的研究方法。初级 完成项目参与的研究人员将有更充分的准备和动力， 在临床神经学方面追求职业和严谨的研究。

Abstract The proposed three-year conference project, centered on the annual clinical research symposium of the Parkinson Study Group (PSG) and associated annual meeting activities, will foster the education and training of early stage investigators to ensure that the highest quality translational and clinical research continues to be conducted toward improved therapy for Parkinson's and related neurological disease. This project goal will be achieved through two specific aims (SAs). In SA #1, the PSG will present its “32nd Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders” in collaboration with the Huntington Study Group (HSG), Dystonia Study Group (DSG), Tourette Syndrome Study Group (TSSG), Cooperative Ataxia Group (CAG), and Tremor Research Group (TRG) on Saturday, April 6, 2019 in Phoenix, AZ, and the 33rd and 34th symposia annually thereafter. The peer-reviewed program includes both platform and poster presentations in a live format with audience participation. The symposia themes will authoritatively address major challenges and opportunities in pursuit of improved treatment for people with Parkinson's and other neurodegenerative diseases, with keynote talks conveying complementary neurobiological, clinical development and patient perspectives. The 2019 Symposium will cover the revolutionary impact of PD genetics, and GBA and LRRK2 mutations in particularly, on PD therapeutics development. SA #2 is designed to provide early-stage clinical investigators with movement disorders training a multi-faceted practical orientation to PD clinical research. The selected junior investigators will participate in several novel and interactive, educational research activities in addition to the symposium, including a) direct exchange with experienced patient advocates of the Parkinson's Foundation's PAIR (Parkinson's Advocates in Research) program to learn how patient input can benefit their research, and b) the PSG Mentoring Committee's junior investigator skills workshop with annually rotating themes spanning clinical research project development, grant proposal writing, and emerging research methodologies. Junior investigators completing participation in the project will be substantially better prepared and motivated to pursue careers and rigorous studies in clinical neurology.